[go: up one dir, main page]

ZA200807626B - Methods for regulating inflammatory mediators and peptides useful therein - Google Patents

Methods for regulating inflammatory mediators and peptides useful therein

Info

Publication number
ZA200807626B
ZA200807626B ZA200807626A ZA200807626A ZA200807626B ZA 200807626 B ZA200807626 B ZA 200807626B ZA 200807626 A ZA200807626 A ZA 200807626A ZA 200807626 A ZA200807626 A ZA 200807626A ZA 200807626 B ZA200807626 B ZA 200807626B
Authority
ZA
South Africa
Prior art keywords
methods
inflammatory mediators
peptides useful
regulating inflammatory
regulating
Prior art date
Application number
ZA200807626A
Other languages
English (en)
Inventor
Takashi Shuji
Pakish Indu
Kenneth B Adler
Linda D Marin
Li Yuehua
Original Assignee
Biomarck Pharmaceutical Ltd
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarck Pharmaceutical Ltd, Univ North Carolina State filed Critical Biomarck Pharmaceutical Ltd
Publication of ZA200807626B publication Critical patent/ZA200807626B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ZA200807626A 2006-03-06 2007-03-06 Methods for regulating inflammatory mediators and peptides useful therein ZA200807626B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/367,449 US7544772B2 (en) 2001-06-26 2006-03-06 Methods for regulating inflammatory mediators and peptides useful therein

Publications (1)

Publication Number Publication Date
ZA200807626B true ZA200807626B (en) 2009-11-25

Family

ID=38475498

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200807626A ZA200807626B (en) 2006-03-06 2007-03-06 Methods for regulating inflammatory mediators and peptides useful therein

Country Status (14)

Country Link
US (2) US7544772B2 (xx)
EP (1) EP1991250A4 (xx)
JP (1) JP2009531307A (xx)
KR (1) KR20090069255A (xx)
CN (1) CN101500593B (xx)
AU (1) AU2007223983A1 (xx)
BR (1) BRPI0708672A2 (xx)
CA (1) CA2645019A1 (xx)
IL (1) IL193846A (xx)
MX (1) MX2008011375A (xx)
RU (1) RU2429004C2 (xx)
SG (2) SG10201405436WA (xx)
WO (1) WO2007103368A2 (xx)
ZA (1) ZA200807626B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501911B2 (en) * 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
EP1799242A4 (en) * 2004-09-16 2009-11-11 Univ California TYPE G PEPTIDES AND OTHER ACTIVE SUBSTANCES TO REDUCE ATHEROSCLEROSIS AND OTHER DISEASES
MX2007006750A (es) 2004-12-06 2007-11-23 Univ California Metodos para mejorar la estructura y funcion de arteriolas.
RU2423379C2 (ru) 2005-01-20 2011-07-10 Байомарк Фармасьютикалз, Лтд. Ингибиторы гиперсекреции муцина и способы их применения
NZ563187A (en) * 2005-04-29 2010-05-28 Univ California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
EP2277899B1 (en) * 2006-04-27 2015-07-08 Singapore Health Services Pte Ltd Antimicrobial peptides
DK2722052T3 (en) * 2006-07-26 2019-04-29 Biomarck Pharmaceuticals Ltd Methods for attenuating the release of inflammatory mediators and peptides useful therein
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2014007547A1 (en) 2012-07-03 2014-01-09 Il Yang Pharm. Co.,Ltd. Novel peptides and use thereof
MX363077B (es) 2013-04-05 2019-03-07 Biomarck Pharmaceuticals Ltd Inhibidores de metastasis.
GB201414910D0 (en) * 2014-05-23 2014-10-08 Mars Inc Composition
USRE50320E1 (en) 2014-07-31 2025-03-04 Uab Research Foundation APOE mimetic peptides and higher potency to clear plasma cholesterol
GB201601136D0 (en) * 2016-01-21 2016-03-09 Mörgelin Matthias And Abdillahi Suado M Novel polypeptides and medical uses thereof
RU2712281C1 (ru) * 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
AU2020298130A1 (en) 2019-06-17 2022-01-20 Biomarck Pharmaceuticals Ltd. Peptides and methods of use thereof in treating uveitis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
AU2240492A (en) 1991-06-20 1993-01-25 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Sequences characteristic of human gene transcription product
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551200A1 (en) 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
US5298506A (en) 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
US5861502A (en) 1992-11-09 1999-01-19 Thomas Jefferson University Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5858981A (en) 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
US5436243A (en) 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
AU709559B2 (en) 1994-04-07 1999-09-02 Proteinix Company Vasoactive intestinal polypeptide
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US6713605B1 (en) * 1996-04-10 2004-03-30 Kansas State University Research Foundation Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
GB9620390D0 (en) 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
DE19716713A1 (de) 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
US7544772B2 (en) 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
DE60014856T2 (de) 1999-02-24 2006-02-02 North Carolina State University Zusammensetzungen zur modulierung der schleimsekretion
US6245320B1 (en) 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
WO2001020998A1 (en) 1999-09-24 2001-03-29 Linden Technologies, Inc. Drug discovery using gene expression profiling
EP1104758B1 (en) 1999-12-03 2003-07-23 Pfizer Products Inc. Acetylene derivatives as anti-inflammatory/analgesic agents
US7919469B2 (en) 2000-02-24 2011-04-05 North Carolina State University Methods and compositions for altering mucus secretion
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
AU2002322475B2 (en) * 2001-06-26 2008-02-21 North Carolina State University Blocking peptide for inflammatory cell secretion
US7598080B2 (en) * 2004-08-20 2009-10-06 Carl Deirmengian Diagnostic assay for source of inflammation
RU2423379C2 (ru) * 2005-01-20 2011-07-10 Байомарк Фармасьютикалз, Лтд. Ингибиторы гиперсекреции муцина и способы их применения

Also Published As

Publication number Publication date
CN101500593B (zh) 2012-08-22
RU2429004C2 (ru) 2011-09-20
MX2008011375A (es) 2008-12-15
US7544772B2 (en) 2009-06-09
KR20090069255A (ko) 2009-06-30
RU2008139414A (ru) 2010-04-20
EP1991250A4 (en) 2012-07-04
US20060217307A1 (en) 2006-09-28
CN101500593A (zh) 2009-08-05
IL193846A0 (en) 2011-08-01
CA2645019A1 (en) 2007-09-13
JP2009531307A (ja) 2009-09-03
US8563689B1 (en) 2013-10-22
SG170082A1 (en) 2011-04-29
AU2007223983A1 (en) 2007-09-13
WO2007103368A2 (en) 2007-09-13
SG10201405436WA (en) 2014-10-30
WO2007103368A3 (en) 2009-04-16
EP1991250A2 (en) 2008-11-19
IL193846A (en) 2015-05-31
BRPI0708672A2 (pt) 2012-05-29

Similar Documents

Publication Publication Date Title
SG10201405436WA (en) Methods for regulating inflammatory mediators and peptides useful therein
AP2942A (en) Compositions and methods for controlling nematodes
SI1982132T1 (sl) Postopek liofilizacije
GB0707068D0 (en) Camera arrangement and method
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
IL197781A0 (en) Lyophilization methods and apparatuses
GB0802474D0 (en) Mutant proteins and methods for selecting them
IL196667A0 (en) Methods for attenuating release of inflammatory mediators and peptides useful therein
GB0700302D0 (en) Method and kit
GB0600967D0 (en) Methods
GB0707069D0 (en) Methods and uses
HK1123730A (en) Methods for regulating inflammatory mediators and peptides useful therein
GB0701037D0 (en) Grooming aid and related methods
GB0610059D0 (en) Uses and methods
GB0617564D0 (en) Peptides and methods
IL185318A0 (en) Engine and methods thereof
GB0901109D0 (en) Mutant proteins and methods for selecting them
GB0621971D0 (en) Improvements in an ehspa architecture
GB0606794D0 (en) Methods and uses
HU3248U (en) Gravestone
GB0724052D0 (en) Mutant proteins and methods for selecting them
GB0621969D0 (en) Improvements in an ehspa architecture
AU2005900073A0 (en) Treatment for autoimmune and inflammatory conditions
GB0722451D0 (en) Methods and uses
GB0707609D0 (en) Methods and uses